Curanex Pharmaceuticals (NASDAQ:CURX) Trading 0.2% Higher – Time to Buy?

Curanex Pharmaceuticals Inc (NASDAQ:CURX) shares rose 0.2% during mid-day trading on Monday . The stock traded as high as $0.2979 and last traded at $0.2660. 52,317 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 85,701 shares. The stock had previously closed at $0.2655.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Curanex Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Curanex Pharmaceuticals presently has an average rating of “Sell”.

Curanex Pharmaceuticals Trading Up 0.2%

The company’s fifty day moving average is $0.34 and its two-hundred day moving average is $0.37. The stock has a market cap of $7.54 million and a price-to-earnings ratio of -0.99.

Curanex Pharmaceuticals (NASDAQ:CURX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) EPS for the quarter.

Hedge Funds Weigh In On Curanex Pharmaceuticals

A hedge fund recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 64,067 shares of the company’s stock, valued at approximately $46,000.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.